OPKO Health, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
OPKO Health, Inc. (OPK) reported Net Income (Loss) Available to Common Stockholders, Diluted of $21.63 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-10-29
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $21.63M, a 31.94% decline year-over-year.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was $31.78M.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$84.47M.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2018-06-30 was -$6.20M.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$153.04M.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$305.25M.
- OPKO Health, Inc. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$52.91M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $21.63M 10-Q · filed 2025-10-29 | |||||
| 2024-09-30 | $31.78M 10-Q · filed 2025-10-29 | -$67.25M 10-Q · filed 2024-11-07 | ||||
| 2023-09-30 | -$84.47M 10-Q · filed 2024-11-07 | -$122.38M 10-Q · filed 2024-11-07 | ||||
| 2018-12-31 | -$153.04M 10-K · filed 2019-03-01 | |||||
| 2018-06-30 | -$6.20M 10-Q · filed 2018-08-07 | -$49.31M 10-Q · filed 2018-08-07 | ||||
| 2017-12-31 | -$305.25M 10-K · filed 2019-03-01 | |||||
| 2017-06-30 | -$21.33M 10-Q · filed 2018-08-07 | -$21.95M 10-Q · filed 2017-08-08 | -$60.14M 10-Q · filed 2018-08-07 | -$57.25M 10-Q · filed 2017-08-08 | ||
| 2016-12-31 | -$41.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$56.46M derived: sum of 2 quarters · filed 2019-03-01 | -$45.20M derived: sum of 3 quarters · filed 2019-03-01 | -$52.91M 10-K · filed 2019-03-01 | ||
| 2016-09-30 | -$14.98M 10-Q · filed 2016-11-07 | -$3.71M derived: sum of 2 quarters · filed 2017-08-08 | -$11.42M 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | $11.27M 10-Q · filed 2017-08-08 | $16.00K 10-Q · filed 2017-08-08 | ||||
| 2015-12-31 | -$20.50M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $72.56M derived: sum of 2 quarters · filed 2019-01-29 | $29.80M derived: sum of 3 quarters · filed 2019-01-29 | -$52.13M 8-K · filed 2019-01-29 | ||
| 2015-09-30 | $93.06M 10-Q · filed 2016-11-07 | $129.03M 10-Q · filed 2015-11-09 | $50.29M derived: sum of 2 quarters · filed 2016-11-07 | -$31.63M 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | -$42.77M 10-Q · filed 2016-08-08 | -$159.88M 10-Q · filed 2016-08-08 | ||||
| 2014-09-30 | -$48.67M 10-Q · filed 2015-11-09 | -$118.69M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |